熊去氧胆酸

Ursodeoxycholic acid
臨床資料
商品名（英语：Drug nomenclature）	Actigall
其他名稱	ursodeoxycholic acid, Actigall, Ursosan, Urso, Urso Forte
AHFS/Drugs.com	Monograph
MedlinePlus	a699047
核准狀況	美 DailyMed: 19396;
懷孕分級	澳: B3 ; ;
给药途径	oral
ATC碼	A05AA02 (WHO) ;
法律規範狀態
法律規範	澳：限医生处方（S4）; 加：处方药（℞-only）; 英：处方药（℞-only） (POM); 美：处方药（℞-only）;
识别信息
	IUPAC命名法 3α,7β-dihydroxy-5β-cholan-24-oic acid; OR; (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-; 10,13-dimethylhexadecahydro-; 1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid; ;
CAS号	128-13-2
PubChem CID	31401;
IUPHAR/BPS	7104;
DrugBank	DB01586 ;
ChemSpider	29131 ;
UNII	724L30Y2QR;
KEGG	D00734 ;
ChEBI	CHEBI:9907 ;
ChEMBL	ChEMBL1551 ;
PDB配體ID	IU5 (PDBe, RCSB PDB);
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID6023731 ;
ECHA InfoCard	100.004.437
化学信息
化学式	C24H40O4
摩尔质量	392.56 g/mol
3D模型（JSmol（英语：JSmol））	交互式图像;
熔点	203 °C（397 °F）
	SMILES O=C(O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]4[C@H]2[C@@H](O)C[C@@H]3C[C@H](O)CC[C@@]34C)C;
	InChI InChI=1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 ; Key:RUDATBOHQWOJDD-UZVSRGJWSA-N ;

熊去氧胆酸（英語：Ursodeoxycholic acid，也被称为3α,7β-二羟基-5β-胆烷-24-羧酸，3α,7β-dihydroxy-5β-cholan-24-oic acid，缩写 UDCA），是一种来自熊膽的胆汁酸^[1]，为次级胆汁酸，由初级胆汁酸经由细菌代谢生成。

它可以降低细胞表面ACE2受体的表达量。^[2]

歷史

熊胆是熊去氧胆酸的天然来源。1955年，日本科学家成功化学合成了熊去氧胆酸^[3]。1987年12月，艾尔建申請的熊去氧胆酸獲准在美國上市。^[4]

参考文献

^ 放過熊吧！可治療膽結石的熊膽早就能用化學合成. 食力 foodNEXT. [2021-12-08]. （原始内容存档于2021-12-08）（中文（臺灣））.
^ Teresa Brevini, Mailis Maes, Gwilym J. Webb, Binu V. John, Claudia D. Fuchs, Gustav Buescher, Lu Wang, Chelsea Griffiths, Marnie L. Brown, William E. Scott, Pehuén Pereyra-Gerber, William T. H. Gelson, Stephanie Brown, Scott Dillon, Daniele Muraro, Jo Sharp, Megan Neary, Helen Box, Lee Tatham, James Stewart, Paul Curley, Henry Pertinez, Sally Forrest, Petra Mlcochova, Sagar S. Varankar, Mahnaz Darvish-Damavandi, Victoria L. Mulcahy, Rhoda E. Kuc, Thomas L. Williams, James A. Heslop, Davide Rossetti, Olivia C. Tysoe, Vasileios Galanakis, Marta Vila-Gonzalez, Thomas W. M. Crozier, Johannes Bargehr, Sanjay Sinha, Sara S. Upponi, Corrina Fear, Lisa Swift, Kourosh Saeb-Parsy, Susan E. Davies, Axel Wester, Hannes Hagström, Espen Melum, Darran Clements, Peter Humphreys, Jo Herriott, Edyta Kijak, Helen Cox, Chloe Bramwell, Anthony Valentijn, Christopher J. R. Illingworth, UK-PBC research consortium, Bassam Dahman, Dustin R. Bastaich, Raphaella D. Ferreira, Thomas Marjot, Eleanor Barnes, Andrew M. Moon, Alfred S. Barritt, Ravindra K. Gupta, Stephen Baker, Anthony P. Davenport, Gareth Corbett, Vassilis G. Gorgoulis, Simon J. A. Buczacki, Joo-Hyeon Lee, Nicholas J. Matheson, Michael Trauner, Andrew J. Fisher, Paul Gibbs, Andrew J. Butler, Christopher J. E. Watson, George F. Mells, Gordon Dougan, Andrew Owen, Ansgar W. Lohse, Ludovic Vallier, Fotios Sampaziotis. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022-12-05 [2022-12-07]. ISSN 0028-0836. doi:10.1038/s41586-022-05594-0. （原始内容存档于2023-06-26）（英语）.
^ Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine. 2009, 5 (1): 2. PMC 2630947  . PMID 19138420. doi:10.1186/1746-4269-5-2.
^ Actigall: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [29 April 2020]. （原始内容存档于2020-10-19）.

外部链接

Ursodeoxycholic acid information （页面存档备份，存于互联网档案馆） at MedlinePlus

[1] 放過熊吧！可治療膽結石的熊膽早就能用化學合成. 食力 foodNEXT. [2021-12-08]. （原始内容存档于2021-12-08）（中文（臺灣））.

[2] Teresa Brevini, Mailis Maes, Gwilym J. Webb, Binu V. John, Claudia D. Fuchs, Gustav Buescher, Lu Wang, Chelsea Griffiths, Marnie L. Brown, William E. Scott, Pehuén Pereyra-Gerber, William T. H. Gelson, Stephanie Brown, Scott Dillon, Daniele Muraro, Jo Sharp, Megan Neary, Helen Box, Lee Tatham, James Stewart, Paul Curley, Henry Pertinez, Sally Forrest, Petra Mlcochova, Sagar S. Varankar, Mahnaz Darvish-Damavandi, Victoria L. Mulcahy, Rhoda E. Kuc, Thomas L. Williams, James A. Heslop, Davide Rossetti, Olivia C. Tysoe, Vasileios Galanakis, Marta Vila-Gonzalez, Thomas W. M. Crozier, Johannes Bargehr, Sanjay Sinha, Sara S. Upponi, Corrina Fear, Lisa Swift, Kourosh Saeb-Parsy, Susan E. Davies, Axel Wester, Hannes Hagström, Espen Melum, Darran Clements, Peter Humphreys, Jo Herriott, Edyta Kijak, Helen Cox, Chloe Bramwell, Anthony Valentijn, Christopher J. R. Illingworth, UK-PBC research consortium, Bassam Dahman, Dustin R. Bastaich, Raphaella D. Ferreira, Thomas Marjot, Eleanor Barnes, Andrew M. Moon, Alfred S. Barritt, Ravindra K. Gupta, Stephen Baker, Anthony P. Davenport, Gareth Corbett, Vassilis G. Gorgoulis, Simon J. A. Buczacki, Joo-Hyeon Lee, Nicholas J. Matheson, Michael Trauner, Andrew J. Fisher, Paul Gibbs, Andrew J. Butler, Christopher J. E. Watson, George F. Mells, Gordon Dougan, Andrew Owen, Ansgar W. Lohse, Ludovic Vallier, Fotios Sampaziotis. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022-12-05 [2022-12-07]. ISSN 0028-0836. doi:10.1038/s41586-022-05594-0. （原始内容存档于2023-06-26）（英语）.

[Feng-3] Feng Y, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine. 2009, 5 (1): 2. PMC 2630947  . PMID 19138420. doi:10.1186/1746-4269-5-2.

[4] Actigall: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [29 April 2020]. （原始内容存档于2020-10-19）.

[1]

[2]

[3]

[4]